FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access M. Alexander Otto, PA, MMSc May 01, 2026

https://www.medscape.com/viewarticle/fda-oks-daraxonrasib-pancreatic-cancer-preapproval-access-2026a1000e26 The FDA has allowed Revolution Medicines to give patients early access to the company’s investigational RAS(ON) inhibitor daraxonrasib for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).